This report consolidates the analyst’s latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the orphan designated drugs in pharma space, as well as providing insights into the leading players and future challengers across the value chain, and providing insights into key drugs and markets from the analyst’s Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future.
Due to the unmet medical demands of many rare diseases around the world, the number of orphan designated drugs (ODD) by regulatory agencies such as the FDA and EMA has increased in recent years. This has arisen from international recognition of the significant number of people that rare diseases affect daily, paired with limited therapeutic options and low patient populations.
As a result, a wide variety of pharmaceutical companies are expanding their orphan drug portfolio through co-development partnerships and collaborations, innovative means of personalized and precision therapy, as well as receiving financial and legal support from regulatory bodies to meet this unmet medical need.
Due to the unmet medical demands of many rare diseases around the world, the number of orphan designated drugs (ODD) by regulatory agencies such as the FDA and EMA has increased in recent years. This has arisen from international recognition of the significant number of people that rare diseases affect daily, paired with limited therapeutic options and low patient populations.
As a result, a wide variety of pharmaceutical companies are expanding their orphan drug portfolio through co-development partnerships and collaborations, innovative means of personalized and precision therapy, as well as receiving financial and legal support from regulatory bodies to meet this unmet medical need.
Scope
- A dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the orphan designated drugs field in pharma landscape.
- This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the orphan designated drugs market.
Reasons to Buy
- Understand the key trends accelerating or hindering the orphan designated drugs in pharma space.
Table of Contents
- Executive Summary
- Players
- Thematic Briefing
- Trends
- Healthcare trends
- Technology trends
- Macroeconomic trends
- Regulatory trends
- Industry Analysis
- Market size and growth forecasts
- Case studies
- Vyxeos Combination for IV Injection Receives Orphan Drug Designation for the Treatment of High-Risk AML in Japan
- Panavance Therapeutics Awarded ODD for its Pancreatic Cancer Treatment
- PhamAust Limited Reveals Encouraging Results for Monepantel
- Can-Fite Biopharma’s Namodenoson Demonstrating Anti-cancer and Protective Effects in the Liver
- Signals
- M&A trends
- Strategic partnerships
- Funding
- Social media trends
- Value Chain
- Drug discovery and development
- Clinical trials
- Manufacturing
- Patient access
- Companies
- Public companies
- Private companies
- Sector Scorecards
- Clinical trials scorecard
- Who’s who
- Thematic screen
- Valuation screen
- Risk screen
- Abbreviations
- Bibliography
- Further Reading
- The analyst reports
- Thematic Research Methodology
- About the Analyst
- Contact the Publisher
Table 1: Healthcare trends
Table 2: Technology trends
Table 3: Macroeconomic trends
Table 4: Regulatory trends
Table 5: M&A trends
Table 6: Strategic partnerships
Table 7: Funding
Table 8: Public companies
Table 9: Private companies
Table 10: Abbreviations
Table 11: the analyst reports
List of Figures
Figure 1: Examples of players in orphan designated drugs and where they sit in the value chain
Figure 2: Global patient-based forecast for orphan designated drugs, 2018-28
Figure 3: Global patient-based forecast for orphan designated drugs by highest generating drugs and indications, 2028
Figure 4: Social media discussions related to orphan designated drugs since 2021
Figure 5: Word cloud with trends related to orphan designated drugs social media discussions
Figure 6: Examples of popular posts related to orphan designated drugs
Figure 7: The orphan designated drugs value chain
Figure 8: Examples of drug discovery and development providers in orphan designated drugs
Figure 9: Examples of clinical trial developers in orphan designated drugs
Figure 10: Examples of manufacturing providers in orphan designated drugs
Figure 11: Examples of patient access developers in orphan designated drugs
Figure 12: Who does what in the orphan designated drugs space?
Figure 13: Our thematic screen ranks companies based on overall leadership in the 10 themes that matter most to their industry, generating a leading indicator of future performance
Figure 14: Our valuation screen ranks our universe of companies within a sector based on selected valuation metrics
Figure 15: Our risk screen ranks companies within a particular sector based on overall investment risk
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Pfizer
- Roche
- AstraZeneca
- Takeda
- Sanofi
- Catalent
- Merck and Co,Argenx
- CSL
- BeiGene
- Ipsen
- Regeneron
- Abzena
- Grifols
- Biogen.
